Commentary: Improvement in diagnostic-therapeutic care pathways for women with migraine: an Italian Delphi panel.

Autor: Viganò A; IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy., Tiberio P; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.; Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy., Diani N; IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy., Zambelli A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.; Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy., Santoro A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.; Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy., De Sanctis R; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.; Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
Jazyk: angličtina
Zdroj: Frontiers in neurology [Front Neurol] 2024 Nov 20; Vol. 15, pp. 1507261. Date of Electronic Publication: 2024 Nov 20 (Print Publication: 2024).
DOI: 10.3389/fneur.2024.1507261
Abstrakt: Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AZ: honoraria for advisory board consultancy from Novartis, AstraZeneca, Lilly, Pfizer, Daiichi Sankyo, MSD, Roche, Seagen, Exact Sciences, Gilead, and Istituto Gentili (all outside the present work); AS: advisory board: Bristol-Myers-Squibb (BMS), Servier, Gilead, Pfizer, Eisai, Bayer, and Merck Sharp and Dohme (MSD). Consultancy: Arqule, Sanofi, and Incyte. Speaker's Bureau: Takeda, BMS, Roche, Abb-Vie, Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, and MSD (all outside the submitted work); RD: honoraria for advisory board consultancy from Novartis, Istituto Clinico Gentili, Amgen, EISAI, Lilly, Gilead, and Ipsen (all outside the present work). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Databáze: MEDLINE